Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

NCT05026736 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped PI request, \<75% participation

Conditions

Locally Advanced Angiosarcoma
Metastatic Angiosarcoma
Recurrent Angiosarcoma

Interventions

OTHER: Quality-of-Life Assessment
BIOLOGICAL: Sintilimab

Sponsor

M.D. Anderson Cancer Center